Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

PRIMARY OBJECTIVES: I. To assess the objective response rate (ORR) to poziotinib according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in non-small cell lung cancer (NSCLC) with EGFR exon 20 mutations. II. Assess the objective response rate (ORR) to poziotinib according to RECIST 1.1 criteria in NSCLC with HER2 (ErBB2) exon 20 mutations. III. Assess the objective response rate (ORR) to poziotinib according to RECIST 1.1 criteria in advanced solid tumors with EGFR exon 20 or HER2 exon 20 mutations. IV. Assess the objective response rate (ORR) to poziotinib according to RECIST 1.1 criteria in advanced solid tumors with HER2 exon 19 mutations ORR will be calculated as the percent of patients whose best confirmed response is complete response (CR, defined as disappearance of all target lesions) or partial response (PR, defined as at least a 30% decrease in the sum of longest diameter \[LD\] of target lesions, taking as reference the baseline sum LD). SECONDARY OBJECTIVES: I. Disease control rate (complete response + partial response + stable response) of poziotinb in cohort 1 and 2, analyzed independently. II. Progression free survival of poziotinb in cohort 1 and 2, analyzed independently. III. Overall survival of poziotinb in cohort 1 and 2, analyzed independently. IV. Duration of response of poziotinb in cohort 1 and 2, analyzed independently. V. Safety and toxicity. EXPLORATORY OBJECTIVES: I. To assess molecular markers associated with resistance and response to poziotinib, including secondary mutations. OUTLINE: Patients receive poziotinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then every 6 months thereafter.